CL2020000859A1 - Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas. - Google Patents

Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.

Info

Publication number
CL2020000859A1
CL2020000859A1 CL2020000859A CL2020000859A CL2020000859A1 CL 2020000859 A1 CL2020000859 A1 CL 2020000859A1 CL 2020000859 A CL2020000859 A CL 2020000859A CL 2020000859 A CL2020000859 A CL 2020000859A CL 2020000859 A1 CL2020000859 A1 CL 2020000859A1
Authority
CL
Chile
Prior art keywords
prevention
treatment
microbial infections
acid derivatives
gluconic acid
Prior art date
Application number
CL2020000859A
Other languages
English (en)
Inventor
Ulf Ellervik
Olov Sterner
Helena Strevens
Sophie Manner
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of CL2020000859A1 publication Critical patent/CL2020000859A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN COMPUESTO DE LA FÓRMULA I PARA SER USADA EN EL TRATAMIENTO Y/O PREVENCIÓN DE INFECCIONES MICROBIANAS. ADEMÁS, LA PRESENTE INVENCIÓN SE REFIERE A UN MÉTODO PARA LA PREVENCIÓN Y/O REDUCCIÓN DE LA FORMACIÓN DE UNA BIOPELÍCULA.
CL2020000859A 2017-10-06 2020-03-31 Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas. CL2020000859A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17195192 2017-10-06

Publications (1)

Publication Number Publication Date
CL2020000859A1 true CL2020000859A1 (es) 2020-10-02

Family

ID=60185986

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000859A CL2020000859A1 (es) 2017-10-06 2020-03-31 Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.

Country Status (17)

Country Link
US (2) US11612584B2 (es)
EP (1) EP3691625A1 (es)
JP (1) JP7424636B2 (es)
KR (1) KR102650182B1 (es)
CN (1) CN111182895B (es)
AU (1) AU2018346361A1 (es)
BR (1) BR112020006931A2 (es)
CA (1) CA3078451A1 (es)
CL (1) CL2020000859A1 (es)
EA (1) EA202090750A1 (es)
IL (1) IL273297B1 (es)
MX (1) MX2020003660A (es)
PH (1) PH12020550222A1 (es)
SG (1) SG11202002494WA (es)
UA (1) UA126590C2 (es)
WO (1) WO2019068862A1 (es)
ZA (1) ZA202001605B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113660928B (zh) 2019-04-05 2024-04-05 盖迪亚生物技术公司 阴道片剂制剂
CN114751878B (zh) * 2022-03-29 2023-06-16 青岛农业大学 一种BcTol1基因靶向剂及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060172007A1 (en) * 2001-05-01 2006-08-03 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20060105008A1 (en) * 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US7547454B2 (en) * 2002-11-07 2009-06-16 Shyam K Gupta Hydroxy acid complexes for antiaging and skin renovation
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
US20050260243A1 (en) * 2004-04-26 2005-11-24 The Procter & Gamble Company Method of treating microbial plant diseases
AU2006209263A1 (en) 2005-09-12 2007-03-29 Mcneil-Ppc, Inc. Anhydrous composition containing an acid-acid buffer system
US20080058421A1 (en) 2006-09-05 2008-03-06 John Alex Lopes Compositions for cleaning and disinfecting nasal tract and sinus cavity
WO2008108834A2 (en) 2006-11-09 2008-09-12 Northwestern University Inhibitors of the mevalonate pathway of streptococcus pneumoniae
JP2008283893A (ja) * 2007-05-16 2008-11-27 Sumitomo Chemical Co Ltd 家禽用コクシジウム感染抑制剤及びそれを用いたコクシジウム感染抑制方法
US20100285095A1 (en) 2009-05-05 2010-11-11 Kimberly Ann Nemeth Hygiene Article Having Calcium Sugar Acid Salt
US9937214B2 (en) 2013-11-08 2018-04-10 Suzhou Osel Bio-Pharm Co., Ltd. Lactobacillus crispatus and application thereof
DK178786B1 (en) 2015-03-11 2017-02-06 Dantrace-Danfeed Ivs Use of zinc and copper gluconate in the treatment of methicillin-resistant staphylococcus aureus
WO2017174731A1 (en) * 2016-04-06 2017-10-12 Gedea Biotech Ab Glucono delta-lactone for treatment of vaginal fungal infections
KR101841976B1 (ko) 2017-06-07 2018-05-14 조영진 식물 추출물을 포함하는 항진균 및 항균 조성물

Also Published As

Publication number Publication date
SG11202002494WA (en) 2020-04-29
MX2020003660A (es) 2020-08-03
EA202090750A1 (ru) 2020-11-11
WO2019068862A1 (en) 2019-04-11
CA3078451A1 (en) 2019-04-11
US20230181523A1 (en) 2023-06-15
KR102650182B1 (ko) 2024-03-21
US11612584B2 (en) 2023-03-28
ZA202001605B (en) 2023-12-20
US20200253925A1 (en) 2020-08-13
CN111182895A (zh) 2020-05-19
KR20200060413A (ko) 2020-05-29
EP3691625A1 (en) 2020-08-12
IL273297B1 (en) 2024-02-01
AU2018346361A1 (en) 2020-05-14
CN111182895B (zh) 2024-05-14
UA126590C2 (uk) 2022-11-02
JP2020536862A (ja) 2020-12-17
JP7424636B2 (ja) 2024-01-30
PH12020550222A1 (en) 2021-02-15
IL273297A (en) 2020-04-30
BR112020006931A2 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
DOP2016000253A (es) Nuevos compuestos
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
ECSP12012201A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CL2020001147A1 (es) Compuestos antibacterianos
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
EA201890419A1 (ru) ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
CL2017002449A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
EA201270547A1 (ru) Фармацевтическая композиция
BR112018071158B8 (pt) Composições tópicas e método para retardar ou inibir a recristalização de ácido 10 hidroxiesteárico ou um sal do mesmo em uma composição tópica
CL2019002203A1 (es) Nuevos compuestos heterocíclicos y sus usos en la prevención o el tratamiento de infecciones bacterianas.
ECSP16095557A (es) Métodos para tratar infecciones